Urso 250 and Acute hepatic failure - a phase IV clinical study of FDA data

Summary:

Acute hepatic failure is reported as a side effect among people who take Urso 250 (ursodiol), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Nexavar, and have Hepatic neoplasm malignant.

The phase IV clinical study analyzes which people have Acute hepatic failure when taking Urso 250. It is created by eHealthMe based on reports of 5,057 people who have side effects when taking Urso 250 from the FDA, and is updated regularly.

What is Urso 250?

Urso 250 has active ingredients of ursodiol. eHealthMe is studying from 5,080 Urso 250 users. Check the latest studies of Urso 250.

What is Acute hepatic failure?

Acute hepatic failure is found to be associated with 710 drugs and 1,184 conditions by eHealthMe. Check the latest studies of Acute hepatic failure.

On Aug, 03, 2026

5,057 people reported to have side effects when taking Urso 250.
Among them, 13 people (0.26%) have Acute hepatic failure.

Could Urso 250 cause Acute hepatic failure?

Among these 13 people:

How long have people been on Urso 250 when they have Acute hepatic failure? *

What is the gender of people who have Acute hepatic failure when taking Urso 250? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Acute hepatic failure when taking Urso 250? *

What are other drugs people take besides Urso 250? *

What are other side effects people have besides Acute hepatic failure? *

Acute Kidney Failure: 6 people, 46.15%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 5 people, 38.46%
Thrombocytopenia (decrease of platelets in blood): 4 people, 30.77%
Fever: 3 people, 23.08%
Pulmonary Oedema (fluid accumulation in the lungs): 3 people, 23.08%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 23.08%
Nausea And Vomiting: 3 people, 23.08%
Mucous Membrane Disorder (disease of mucous membrane): 3 people, 23.08%
Infection: 3 people, 23.08%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 23.08%

What are the existing conditions these people have? *

Hepatic Neoplasm Malignant (liver cancer): 3 people, 23.08%
Hepatitis C: 2 people, 15.38%
Asthma: 2 people, 15.38%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 15.38%
Schizophrenia, Catatonic Type (a type (or subtype) of schizophrenia that includes extremes of behaviour): 1 person, 7.69%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.69%
Psychiatric Symptom: 1 person, 7.69%
Hepatic Neoplasm Malignant Recurrent (liver cancer-recurrent): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Urso 250 and have Acute hepatic failure?

- Check whether Acute hepatic failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Urso 250:

Urso 250 (5,080 reports)

Browse all side effects of Urso 250:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute hepatic failure:

Acute hepatic failure (710 drugs)

Browse all the conditions that are associated with Acute hepatic failure:

Acute hepatic failure (1,184 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ursodiol (the active ingredients of Urso 250) and Urso 250 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.